Idaho Technology Receives FDA 510(k) Clearance for Expanded FilmArray Respiratory Panel
SALT LAKE CITY, May 15, 2012 (GLOBE NEWSWIRE) — Idaho
Technology, Inc., a privately held clinical diagnostics company
dedicated to providing the world’s fastest, highest-quality
instruments for pathogen identification and DNA analysis,…
Read the original here: Idaho Technology Receives FDA 510(k) Clearance for Expanded FilmArray Respiratory Panel
Large-Scale Meta-Analysis Shows Age Not a Social Barrier to Opioid Use and Misuse
Review of 725,000 prescription drug monitoring samples
demonstrate older patient population — particularly “Boomers” –
are at risk for Rx misuse, abuse and drug interactions
BALTIMORE, May 17, 2012 /PRNewswire/ — Ameritox (SM), the
nation’s…
See more here: Large-Scale Meta-Analysis Shows Age Not a Social Barrier to Opioid Use and Misuse
Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
MALVERN, Pa. and MAHWAH, N.J., May 17, 2012 /PRNewswire/ –
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) (“Auxilium”) and FCB
I LLC (“FCB”) today announced that the United States Patent and
Trademark Office (“USPTO”) has issued U.S. Patent No….
Read the original here: Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
Bionest Publishes Landmark Article on Quantitative Financial Analysis of Personalized Medicine Strategies
Nature Reviews article details a comprehensive
approach for analyzing and modeling biomarker-based personalized
medicine strategies to enable decision-making
NEW YORK & PARIS–(BUSINESS WIRE)–May 18, 2012 – Bionest
Partners, a premier strategy…
Dr. Reddy’s Announces the Launch of Clopidogrel Tablets, USP
HYDERABAD, India–(BUSINESS WIRE)–May 18, 2012 – Dr. Reddy’s
Laboratories (NYSE: RDY) announced today that it has launched
CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a
bioequivalent generic version of PLAVIX?, in the
U.S. market on May 18,…
Read more: Dr. Reddy’s Announces the Launch of Clopidogrel Tablets, USP
Actavis Launches First Generic Equivalent of Requip XL (Ropinirole Extended-Release Tablets)
MORRISTOWN, N.J., May 18, 2012 /PRNewswire/ — Actavis Group, an
international generic pharmaceuticals company, today announced that
it received US FDA approval of Ropinirole Extended-Release Tablets,
2mg, 4mg, 6mg, 8mg and 12mg, a generic…
Original post: Actavis Launches First Generic Equivalent of Requip XL (Ropinirole Extended-Release Tablets)
Novo Nordisk Celebrates New INDYCAR Partnership Featuring Indy 500-Themed Billboard in Times Square
INDIANAPOLIS–(BUSINESS WIRE)–May 18, 2012 – Novo Nordisk, a
world leader in diabetes care, announced today that it has expanded
its motorsports initiatives to include an official partnership with
INDYCAR. The healthcare company is now the official…
Read more here: Novo Nordisk Celebrates New INDYCAR Partnership Featuring Indy 500-Themed Billboard in Times Square
Mylan Launches Generic Version of Plavix Tablets
-Company Will Have 180 Days of Marketing Exclusivity for the 300
mg Strength-
PITTSBURGH, May 17, 2012 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL)
today announced that its subsidiary Mylan Pharmaceuticals Inc. has
received final approval from the U.S….
Read more: Mylan Launches Generic Version of Plavix Tablets
Watson Confirms Lo Loestrin Fe Patent Challenge
- Paragraph IV Litigation Underway -
PARSIPPANY, N.J., May 18, 2012 /PRNewswire/ — Watson
Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its
subsidiary, Watson Laboratories, Inc., filed an Abbreviated New
Drug Application (ANDA) with the…
Continued here: Watson Confirms Lo Loestrin Fe Patent Challenge
Baron and Budd Warns Women About Side Effects of YAZ, Yasmin
FDA Requires New Warnings for YAZ, Yasmin Regarding Blood
Clots
DALLAS–(BUSINESS WIRE)–May 16, 2012 – The Federal Drug
Administration (FDA) has recently decided to strengthen warning
labels on the oral contraceptive
YAZ and its sister drug Yasmin…
Read the original post: Baron and Budd Warns Women About Side Effects of YAZ, Yasmin